AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Conference Call February 07, 2020 Corporate Participants: Liz Shea -- Vice President of Investor Relations Richard A. Gonzalez -- Chairman
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Call Transcript
Categories
Health Care
Eli Lilly & Co (NYSE: LLY) Q4 2019 Earnings Call Transcript
Eli Lilly & Co (NYSE: LLY) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Kevin Hern -- Vice President of Investor Relations David
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Call Transcript
Amgen Inc (NASDAQ: AMGN) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Arvind Sood -- Vice President of Investor Relations Robert A. Bradway -- Chairman
Neovasc (NVCN) Q4 2019 Earnings Snapshot
-- Neovasc (NASDAQ: NVCN) reported a comprehensive loss of $1.45 per share for Q4 2019 vs. a loss of $5.07 per share
Titan Pharmaceuticals, Inc. (TTNP): Q4 2019 Earnings Snapshot
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with
Pfizer Inc (NYSE: PFE) Q4 2019 Earnings Call Transcript
Pfizer Inc (NYSE: PFE) Q4 2019 Earnings Conference Call January 28, 2020 Corporate participants: Chuck Triano -- Senior Vice President, Investor Relations Albert Bourla -- Chairman
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Jan. 22, 2020 Corporate Participants: Christopher DelOrefice -- Vice President of Investor Relations Alex Gorsky -- Chairman,
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Call Transcript
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Conference Call February 26, 2020 Corporate Participants: Stephanie C. Diaz -- President and Chief Executive Officer Brian
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Call Transcript
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Conference Call February 04, 2020 Corporate Participants: Douglas Maffei -- Investor Relations Daniel O'Day -- Chairman and Chief Executive
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
Companies that are working on the coronavirus vaccine
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone.
Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19
Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The
Ocugen (OCGN) posts narrower-than-expected loss in FY19
Ocugen, Inc. (NASDAQ: OCGN) reported a wider loss in fiscal 2019 due to expenses related to the change in fair value of
How to go stock picking in a coronavirus-infected market
Arguably the most iconic statement made by Warren Buffett to date is – “We simply attempt to be fearful when others are
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Call Transcript
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz -- Senior Director of Investor Relations John
Biocept (BIOC) posts wider-than-expected loss in Q4
Biocept, Inc. (NASDAQ: BIOC) reported a narrower loss in the fourth quarter of 2019 driven by higher revenue. The bottom line was
Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot
-- Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. -- Net loss
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects
Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer
Why investors need to take note as Veru Inc transforms into a prostate cancer firm
According to the American Cancer Society, prostate cancer is the second most common form of cancer among men in the US, affecting almost
Baxter International (BAX): Q4 2019 Earnings Snapshot
-- Baxter International Inc. (NYSE: BAX) reported Q4 2019 earnings of $0.97 per share, up 37% from last year. -- Worldwide sales